2008
DOI: 10.1016/j.ejphar.2008.06.100
|View full text |Cite
|
Sign up to set email alerts
|

Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
17
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 42 publications
(19 citation statements)
references
References 33 publications
2
17
0
Order By: Relevance
“…The antipsychotic aripiprazole antagonizes ethanoland amphetamine-induced locomotor stimulation in mice (50) and significantly suppresses locomotor activity in naïve animals as reported in a previous investigation (51) and this study. Moreover, other experimental results suggest the possible therapeutic application of aripiprazole to reduce the severity of morphine-induced adverse effects relating to dopaminergic neuronal activity such as morphine-induced hyperlocomotion and reward (52).…”
Section: Discussionmentioning
confidence: 50%
“…The antipsychotic aripiprazole antagonizes ethanoland amphetamine-induced locomotor stimulation in mice (50) and significantly suppresses locomotor activity in naïve animals as reported in a previous investigation (51) and this study. Moreover, other experimental results suggest the possible therapeutic application of aripiprazole to reduce the severity of morphine-induced adverse effects relating to dopaminergic neuronal activity such as morphine-induced hyperlocomotion and reward (52).…”
Section: Discussionmentioning
confidence: 50%
“…More telling, SSRIs fail to reduce symptomology in 40-60% of OCD patients (Pallanti and Quercioli 2006), although benzodiazepines were even less effective (Goddard et al 2008). The clear implication is that OCD is a complex disorder that involves multiple systems rather the current emphasis on the serotonin receptor (Egashira et al 2008, Marazziti et al 2010, Takeuchi et al 2002.…”
Section: Discussionmentioning
confidence: 99%
“…We decided to use doses within the medium to high range of those used in mammals (Niesink and Van Ree, 1982;Scotti de Carolis et al, 1986;Schechter, 1988;Hagan et al, 1997;Guscott et al, 2003;Morita et al, 2005;Freitas et al, 2006;Egashira et al, 2008).…”
Section: Effect Of Intraperitoneal Administration Of Pharmacological mentioning
confidence: 99%